Orlistat
- Generic Name
- Orlistat
- Brand Names
- Alli, Xenical, Alli (previously Orlistat GSK)
- Drug Type
- Small Molecule
- Chemical Formula
- C29H53NO5
- CAS Number
- 96829-58-2
- Unique Ingredient Identifier
- 95M8R751W8
- Background
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.
...
- Indication
Orlistat is indicated for obesity management including weight loss and weight maintenance when used in combination with calorie reduction in overweight and obese adults; this indication applies to both the prescription formulation of 120 mg and the over-the-counter formulation of 60 mg. Orlistat in the 120 mg prescription formulation is also indicated to red...
- Associated Conditions
- Weight Gain
- Associated Therapies
- Weight Reduction
Efficacy and Safety of ATL-962 in Obese Diabetics
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2006-08-29
- Lead Sponsor
- Alizyme
- Target Recruit Count
- 600
- Registration Number
- NCT00156897
- Locations
- 🇫🇮
Obesity Research Unit, Helsinki, Finland
🇫🇮Oy Foodfiles Limited, Kuopio, Finland
🇫🇮Oulun Diakonissalaitos, Oulu, Finland
The Effect of Xenical on Weight and Risk Factors
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2013-04-01
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 25
- Registration Number
- NCT00152360
- Locations
- 🇨🇦
Healthy Heart Program/Lipid Clinic, St. Paul's Hospital, Vancouver, British Columbia, Canada
A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
- Conditions
- Interventions
- First Posted Date
- 2005-04-18
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- US Department of Veterans Affairs
- Target Recruit Count
- 146
- Registration Number
- NCT00108524
- Locations
- 🇺🇸
Durham VA Medical Center HSR&D COE, Durham, North Carolina, United States
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
- Conditions
- Interventions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Jack Yanovski
- Target Recruit Count
- 200
- Registration Number
- NCT00001723
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.